AstraZeneca allied with Starpharma on drug delivery, in a licensing deal that could yield the Australian company up to $126 million from the development and commercialization of one of the Big Pharma's oncology candidates, and up to $93.3 million for each subsequent product.
AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
A targeting technology developed by Australian company Starpharma Holdings has delivered tumor levels of Sanofi Aventis' anticancer drug docetaxel (Taxotere) that are higher and longer-lasting than those seen with the current formulation.
Under the terms of the agreement, AstraZeneca will test Starpharma drug-dendrimer conjugate molecules as potential anti-cancer agents.
Eli Lilly ($LLY) is doubling down on efforts to tap into other firms' drug delivery technology for its own development efforts. The pharmaceutical giant will expand a 2010 deal with Australia's
Investigators for Australia's Starpharma and the Monash Institute of Pharmaceutical Sciences have picked up a sizeable new grant to finance a fresh round of research on the use of dendrimers for